
SAN DIEGO-“When do you start HIV therapy and what do you start with?” Michael S. Saag, MD, asked to open a seminar on retroviral therapy at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). As simplistic as it sounds, he said, it is a question that initiates the process of strategic thinking on the use of antiretroviral therapy.
